Treatment Pathway and Clinical Outcomes of the Population with Muscle-invasive Bladder Cancer in Italy: A Real-world Analysis with Administrative Databases
Advances in Therapy · 2026
DOI: 10.1007/s12325-025-03420-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Therapy, 2026. Verfasst von Paolo Luraghi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, AstraZeneca, Milan, Italy. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Cystectomy. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Astrazeneca.
Abstract (Originalsprache)
INTRODUCTION: In Italy, real-world data on muscle-invasive bladder cancer (MIBC) are scanty. This analysis exploited administrative databases to describe the clinical characteristics and treatment outcomes of patients with MIBC. METHODS: Adults hospitalized for non-metastatic bladder cancer who underwent cystectomy in 2018 were proxied for MIBC. The following variables were examined: demographic and clinical characteristics, number of transurethral resections of the bladder tumor (TURBs) and time to cystectomy to discriminate de novo diagnoses from progressions; chemotherapy ± 6 months before/after cystectomy to distinguish neoadjuvant or adjuvant regimens; creatinine clearance (CrCl) as an indicator of renal function for cisplatin eligibility; disease-free survival (DFS) and overall survival (OS) using Kaplan-Meier method. RESULTS: Among 394 patients included, 79.4% were men; mean age was 72.5 years and Charlson comorbidity index (CCI) 0.6. Three hundred thirty-nine (86%) had ≥ 1 TURBs pre-cystectomy: 222 (56%) were de novo diagnoses and 117 (30%) progressions from non-muscle-invasive disease. After stratification by CrCl ( 75 years) burdened by comorbidities. Treatment choice was influenced by other factors rather than cisplatin eligibility since only 11% of patients with CrCl ≥ 60 ml/min in 2018 and 20% in 2022 were treated before cystectomy, highlighting a scenario of low adherence to guidelines with underutilization of neoadjuvant chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, AstraZeneca, Milan, Italy.
- CliCon S.R.L. Società Benefit, Health, Economics & Outcomes Research, Via Murri 9, 40137, Bologna, Italia. valentina.perrone@clicon.it.
- CliCon S.R.L. Società Benefit, Health, Economics & Outcomes Research, Via Murri 9, 40137, Bologna, Italia.
- Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
- Clinical Oncology, Azienda Ospedaliera Universitaria Careggi, Florence, Italy.
ORCID-Profile: Valentina Perrone, Luca Degli Esposti
Förderung
- Astrazeneca
Zitieren
APA
Luraghi, P., Perrone, V., Castelletti, D., Losi, S., Risi, M., Mazzoni, S., Esposti, L. D., & Antonuzzo, L. (2026). Treatment Pathway and Clinical Outcomes of the Population with Muscle-invasive Bladder Cancer in Italy: A Real-world Analysis with Administrative Databases. Advances in Therapy. https://doi.org/10.1007/s12325-025-03420-3
Vancouver
Luraghi P, Perrone V, Castelletti D, Losi S, Risi M, Mazzoni S, et al. Treatment Pathway and Clinical Outcomes of the Population with Muscle-invasive Bladder Cancer in Italy: A Real-world Analysis with Administrative Databases. Advances in Therapy. 2026. doi:10.1007/s12325-025-03420-3
BibTeX
@article{Luraghi2026,
author = {Luraghi, Paolo and Perrone, Valentina and Castelletti, Daniela and Losi, Serena and Risi, Matteo and Mazzoni, Stefania and Esposti, Luca Degli and Antonuzzo, Lorenzo},
title = {Treatment Pathway and Clinical Outcomes of the Population with Muscle-invasive Bladder Cancer in Italy: A Real-world Analysis with Administrative Databases},
journal = {Advances in Therapy},
year = {2026},
doi = {10.1007/s12325-025-03420-3}
}
EUVIMED